Gavilá, Joaquín
Oliveira, Mafalda
Pascual, Tomás
Perez-Garcia, Jose
Gonzàlez, Xavier
Canes, Jordi
Paré, Laia
Calvo, Isabel
Ciruelos, Eva
Muñoz, Montserrat
Virizuela, Juan A.
Ruiz, Isabel
Andrés, Raquel
Perelló, Antonia
Martínez, Jerónimo
Morales, Serafín
Marín-Aguilera, Mercedes
Martínez, Débora
Quero, Juan C.
Llombart-Cussac, Antonio
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Funding for this research was provided by:
Instituto de Salud Carlos III (PI16/00904)
Teva Pharmaceutical Industries (Not applicable)
F. Hoffmann-La Roche (Not applicable)
Pas a Pas (Not applicable)
Save the mama (Not applicable)
Article History
Received: 20 August 2018
Accepted: 10 December 2018
First Online: 9 January 2019
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of Hospital Vall d’Hebron (Barcelona) AC/R(AG)143/2012(3455). All patients provided written informed consent.
: Not applicable.
: Advisory role of AP for Nanostring Technologies. Advisory Role of JG for Roche. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.